Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
- Conditions
- GastroparesisDiabetes
- First Posted Date
- 2006-10-23
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 40
- Registration Number
- NCT00390975
- Locations
- 🇺🇸
The University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸The University of Louisville, Louisville, Kentucky, United States
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00390520
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
- Conditions
- Heartburn
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 576
- Registration Number
- NCT00390390
- Locations
- 🇺🇸
Palm Beach Research, West Palm Beach, Florida, United States
🇺🇸Medical Edge Healthcare Group, Dallas, Texas, United States
🇺🇸Gaslamp Medical Center, San Diego, California, United States
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
- Conditions
- Heartburn
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2007-04-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 576
- Registration Number
- NCT00389948
- Locations
- 🇺🇸
William W. Anderson M.D. P.C., Rio Rancho, New Mexico, United States
🇺🇸Benchmark Research, San Angelo, Texas, United States
🇺🇸Micheal Alexander, DO, Columbus, Ohio, United States
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2008-11-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00389415
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 726
- Registration Number
- NCT00387517
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.
- Conditions
- MalariaFalciparum
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 890
- Registration Number
- NCT00386763
- Locations
- 🇹🇿
Novartis, Tanzania, Tanzania
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
- Conditions
- Hypertension
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 881
- Registration Number
- NCT00386139
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 601
- Registration Number
- NCT00386607
- Locations
- 🇳🇱
Investigative Centers, Netherlands, Netherlands
Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin
- Conditions
- DyslipidemiaHypertensionHypercholesterolemia
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00385931
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States